Roche, Zealand Pharma obesity drug meets clinical trial weight loss target, but can it compete?

Petrelintide released phase 2 results showing it was tolerable as well as placebo, but average weight loss was lower than analysts expected. The Zealand Pharma drug is a peptide developed in partnership with Roche and is designed to activate the amylin receptor.

Roche, New Zealand drugmaker's obesity drug meets clinical trial weight loss target, but can it compete? appeared first on MedCity News.